中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
12期
793-796
,共4页
张晓辉%徐雅莉%孙强%潘博%周易冬%茅枫%关竞红%林燕
張曉輝%徐雅莉%孫彊%潘博%週易鼕%茅楓%關競紅%林燕
장효휘%서아리%손강%반박%주역동%모풍%관경홍%림연
乳腺癌%分子分型%生存%预后
乳腺癌%分子分型%生存%預後
유선암%분자분형%생존%예후
breast cancer%subtype%survival%prognosis
目的:探讨腋窝淋巴结阴性浸润性乳腺癌不同分子分型的分布,临床病理特征以及和预后的关系。方法:回顾性分析183例该类乳腺癌患者的临床病理资料,对管腔上皮(Luminal)型、基底样(Basal-1ike)型和HER-2过表达(over-expression)型乳腺癌患者在年龄、肿瘤大小、临床分期和无瘤生存率(disease-free survival,DFS)、总生存率(overall survival,OS)方面进行统计分析。结果:不同分子亚型乳腺癌在年龄、肿瘤大小、临床分期方面无显著性差异。Luminal、Basal-like、HER-2过表达型的复发率分别为3.9%(4/102)、20.4%(10/49)、6.3%(2/32)(P=0.002);死亡率分别为2.0%(2/102)、6.1%(3/49)、3.1%(1/32)(P>0.05)。Ka-plan-Meier分析显示Basal-like型的DFS最低(P=0.002),Basal-like型的OS较低(P=0.39)。Cox多因素比例风险模型分析显示分子亚型对DFS存在显著影响(P=0.001)。结论:在腋窝淋巴结阴性浸润性乳腺癌患者中,不同分子亚型在年龄、肿瘤大小及临床分期方面无显著性差异,Basal-like型预后最差,分子分型是其独立预后指标。
目的:探討腋窩淋巴結陰性浸潤性乳腺癌不同分子分型的分佈,臨床病理特徵以及和預後的關繫。方法:迴顧性分析183例該類乳腺癌患者的臨床病理資料,對管腔上皮(Luminal)型、基底樣(Basal-1ike)型和HER-2過錶達(over-expression)型乳腺癌患者在年齡、腫瘤大小、臨床分期和無瘤生存率(disease-free survival,DFS)、總生存率(overall survival,OS)方麵進行統計分析。結果:不同分子亞型乳腺癌在年齡、腫瘤大小、臨床分期方麵無顯著性差異。Luminal、Basal-like、HER-2過錶達型的複髮率分彆為3.9%(4/102)、20.4%(10/49)、6.3%(2/32)(P=0.002);死亡率分彆為2.0%(2/102)、6.1%(3/49)、3.1%(1/32)(P>0.05)。Ka-plan-Meier分析顯示Basal-like型的DFS最低(P=0.002),Basal-like型的OS較低(P=0.39)。Cox多因素比例風險模型分析顯示分子亞型對DFS存在顯著影響(P=0.001)。結論:在腋窩淋巴結陰性浸潤性乳腺癌患者中,不同分子亞型在年齡、腫瘤大小及臨床分期方麵無顯著性差異,Basal-like型預後最差,分子分型是其獨立預後指標。
목적:탐토액와림파결음성침윤성유선암불동분자분형적분포,림상병리특정이급화예후적관계。방법:회고성분석183례해류유선암환자적림상병리자료,대관강상피(Luminal)형、기저양(Basal-1ike)형화HER-2과표체(over-expression)형유선암환자재년령、종류대소、림상분기화무류생존솔(disease-free survival,DFS)、총생존솔(overall survival,OS)방면진행통계분석。결과:불동분자아형유선암재년령、종류대소、림상분기방면무현저성차이。Luminal、Basal-like、HER-2과표체형적복발솔분별위3.9%(4/102)、20.4%(10/49)、6.3%(2/32)(P=0.002);사망솔분별위2.0%(2/102)、6.1%(3/49)、3.1%(1/32)(P>0.05)。Ka-plan-Meier분석현시Basal-like형적DFS최저(P=0.002),Basal-like형적OS교저(P=0.39)。Cox다인소비례풍험모형분석현시분자아형대DFS존재현저영향(P=0.001)。결론:재액와림파결음성침윤성유선암환자중,불동분자아형재년령、종류대소급림상분기방면무현저성차이,Basal-like형예후최차,분자분형시기독립예후지표。
Objective:To analyze the distribution, clinico-pathologic features, and survival status of different subtypes in axillary lymph node-negative invasive breast cancer patients. Methods:In this study, data of 183 patients were included and retrospectively ana-lyzed in terms of age distribution, clinico-pathologic features, disease-free survival (DFS), and overall survival based on different sub-types (luminal, basal-like, and HER-2 over-expression). Results:No significant differences in age, tumor size, and TNM stage was ob-served among different subtypes. The relapse rates of luminal, basal-like, and HER-2 over-expression subtypes were 3.9% (4/102), 20.4% (10/49), and 6.3% (2/32), respectively (P=0.002). The death rates of luminal, basal-like, and HER-2 over-expression subtypes were 2.0%(2/102), 6.1%(3/49), and 3.1%(1/32), respectively (P>0.05). Kaplan-Meier analysis showed that the DFS of basal-like sub-type was much lower compared with that of the luminal and HER-2 over-expression subtypes (P=0.002). Cox analysis showed that the subtype was an independent prognostic indicator (P=0.001). Conclusion:In node-negative invasive breast cancer, no significant differ-ences in age distribution, tumor size, and TNM stage was observed among different subtypes. The basal-like subtype has the worst prog-nosis. Therefore, subtype is an important independent prognostic indicator.